Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas by Tomasz Kolenda, Kacper Guglas, Magda Kopczyńska, Anna Teresiak, Renata Bliźniak, Andrzej Mackiewicz, Katarzyna Lamperska, Jacek Mackiewicz

“…The <i>ZFAS1</i> levels typically differed depending on the cancer stage and T-stage. Patients with a lower expression of <i>ZFAS1</i> presented a slightly longer disease-free survival and overall survival. …”
Get full text

Direct Oral Anticoagulants Are Associated with Superior Survival Outcomes than Warfarin in Patients with Head and Neck Cancers by Chien-Lin Lee, Wei-Shan Chen, Yinshen Wee, Ching-Shuen Wang, Wei-Chih Chen, Tai-Jan Chiu, Yu-Ming Wang, Ching-Nung Wu, Yao-Hsu Yang, Sheng-Dean Luo, Shao-Chun Wu

“…Patients with oropharyngeal and laryngeal cancer and DOAC users had a significantly lower hazard ratio for survival, whereas patients with American Joint Committee on Cancer stage IV disease and those receiving multidisciplinary treatment (e.g., surgery with radiotherapy or concurrent radiochemotherapy) had a significantly higher hazard ratio for survival. …”
Get full text

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer by Kai Conrad Cecil Johnson, Daniel Goldstein, Jasmin Tharakan, Dionisia Quiroga, Mahmoud Kassem, Michael Grimm, Abdul Miah, Craig Vargo, Michael Berger, Preeti Sudheendra, Ashley Pariser, Margaret E. Gatti-Mays, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Bhuvaneswari Ramaswamy, Gary Tozbikian, Patrick M. Schnell, Mathew A. Cherian

“…The majority were nondiabetic (80.2%). For cancer stage, 69.8% (n = 81) had stage 2 breast cancer. …”
Get full text

Preliminary results of hypofractionated radiotherapy in breast cancer in Chandigarh, India: single-centre, non-inferiority, open-label, randomised, phase 3 trialResearch in context by Budhi Singh Yadav, Divya Dahiya, Manish Gupta, Ankita Gupta, Arun S. Oinam, Siddhant Khare, Santhosh Irrinki, Ngangom Robert, Yashwant Raj Sakaray, Satish S. Nagaraj, Reena Kumari

“…Patients with breast cancer, stage I-III, post mastectomy or after breast conservative surgery who needed adjuvant locoregional radiotherapy were randomised in the Department of Radiotherapy &amp; Oncology, Post Graduate Institute of Medical Education &amp; Research (PGIMER), Chandigarh, India; to 34Gy in 10 fractions over 2 weeks (2-week arm) or 35Gy in 15 fractions over 3 weeks to the chest wall and 40Gy/15#/3wks to breast and supraclavicular fossa (3-week arm). …”
Get full text

Long Non-Coding RNA LEF1-AS1 Promotes Migration, Invasion and Metastasis of Colon Cancer Cells Through miR-30-5p/SOX9 Axis [Retraction] by Sun T, Liu Z, Zhang R, Ma S, Lin T, Li Y, Yang S, Zhang W, Wang Y

“…PLoS ONE. 2013;8(10):e77107. https://doi.org/10.1371/journal.pone.0077107; Wang Y, Yin Y, Zhou H, Cao Y. miR&#x2011;639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma. …”
Get full text

Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study by Yang Yang, Junping Yin, Jian Li, Bo Liu, Ming Li, Qiao Huang, Xianglin Yuan, Christian Kurts, Guangyuan Hu, Qi Mei, Xi Tang, Alexander Böhner, Amy Bryant

“…After matching for age, gender, cancer stage/types, comorbidity and performance status, 1060 patients (530 pairs) were selected for propensity score match analysis. …”
Get full text

Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets by Yongli Situ, Quanyan Liang, Ziying Zeng, Jv Chen, Zheng Shao, Qinying Xu, Xiaoyong Lu, Yongshi Cui, Juying Zhang, Lingling Lu, Li Deng

“…We also provided useful information on BRD2, BRD3, and BRD4 and potential new targets for the clinical treatment of ACC.MethodsWe systematically analyzed the expression, prognosis, gene regulatory network, and regulatory targets of BRD2, BRD3, and BRD4 in ACC using multiple online databases, including cBioPortal, TRRUST, GeneMANIA, GEPIA, Metascape, UALCAN, LinkedOmics, and TIMER.ResultsThe expression levels of BRD3 and BRD4 were significantly upregulated in ACC patients at different cancer stages. Moreover, the expression of BRD4 was significantly correlated with the pathological stage of ACC. …”
Get full text

PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets by Zheng Shao, Lingling Lu, Yongshi Cui, Li Deng, Qinying Xu, Quanyan Liang, Xiaoyong Lu, Juying Zhang, Jv Chen, Yongli Situ

“…Results: The expression levels of PYCR1, PYCR2, and PYCRL were considerably upregulated in patients with KIRP based on sample type, sex, age, and individual cancer stage. PYCR1 and PYCR2 transcript levels were markedly upregulated in females than in males, and patients aged 21–40 years had higher PYCR1 and PYCR2 transcript levels than those in other age groups. …”
Get full text

Potential diagnostic of lymph node metastasis and prognostic values of TM4SFs in papillary thyroid carcinoma patients by Kun Wang, Kun Wang, Haomin Li, Junyu Zhao, Jinming Yao, Yiran Lu, Jianjun Dong, Jie Bai, Lin Liao, Lin Liao

“…Finally, we explored the correlation between TM4SFs and TMB/MSI.Results: We identified 21 DEGs from the 41 TM4SFs between N0 (without LNM) and N1 (with LNM) patients, with TM4SF1, TM4SF4, UPK1B, and CD151 being highly expressed in the N1 group; several DEGs were observed in the TNM, T, and N cancer stages. The “integrins and other cell-surface receptors” pathway was the most significantly enriched functional category related to LNM and TM4SFs. …”
Get full text

Investigating high circulating IGF-1 as a risk factor for development of prostate cancer by Nandakumar, AM

“…IGF-1 did cause persistent increase in nuclear IGF-1R, which has been associated with advanced prostate cancer stage. Secondly, I tested effects of IGF-1 on the immune mediators in prostate cancer cell cultures. …”

Hand grip strength in patients with advanced cancer: A prospective study by Sara Hadzibegovic, Jan Porthun, Alessia Lena, Pia Weinländer, Laura C. Lück, Sophia K. Potthoff, Lukas Rösnick, Ann‐Kathrin Fröhlich, Luisa Valentina Ramer, Frederike Sonntag, Ursula Wilkenshoff, Johann Ahn, Ulrich Keller, Lars Bullinger, Amir A. Mahabadi, Matthias Totzeck, Tienush Rassaf, Stephan vonHaehling, Andrew J.S. Coats, Stefan D. Anker, Eric J. Roeland, Ulf Landmesser, Markus S. Anker

“…Reduced maximal HGS was associated with increased mortality (per −5 kg; hazard ratio [HR] 1.19; 1.10–1.28; P < 0.0001; independently of age, sex, cancer stage, cancer entity and presence of cachexia). …”
Get full text

SHMT as a Potential Therapeutic Target for Renal Cell Carcinoma by Yongli Situ, Juying Zhang, Wenyu Liao, Quanyan Liang, Lingling Lu, Qinying Xu, Jv Chen, Xiaoyong Lu, Yongshi Cui, Zheng Shao, Li Deng

“…Results: SHMT1 and SHMT2 transcript levels were significantly down- and upregulated, respectively, in patients with KICH, KIRC, and KIRP, based on sample type, individual cancer stage, sex, and patient age. Compared to men, women with KIRC and KIRP showed significantly up- and downregulated SHMT1 transcript levels, respectively. …”
Get full text

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutationsResearch in context by Yu Jiang, Yuechun Lin, Wenhai Fu, Qihua He, Hengrui Liang, Ran Zhong, Ran Cheng, Bingliang Li, Yaokai Wen, Huiting Wang, Jianfu Li, Caichen Li, Shan Xiong, Songan Chen, Jianxing Xiang, Michael J. Mann, Jianxing He, Wenhua Liang

Get full text

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analy... by Tan, Darren Jun Hao, Ng, Cheng Han, Lin, Snow Yunni, Pan, Xin Hui, Tay, Phoebe, Lim, Wen Hui, Teng, Margaret, Syn, Nicholas, Lim, Grace, Yong, Jie Ning, Quek, Jingxuan, Xiao, Jieling, Dan, Yock Young, Siddiqui, Mohammad Shadab, Sanyal, Arun J., Muthiah, Mark D., Loomba, Rohit, Huang, Daniel Q

“…Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0·0087), were more likely to have uninodular lesions (p=0·0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Eastern Cooperative Oncology Group (ECOG) performance status to patients with non-NAFLD-related hepatocellular carcinoma. …”
Get full text

Diagnostic significance of CA-62 cancer antigen for early detection and differential diagnosis of non-small cell lung cancer: results of the blind clinical trials by Janneta R. Tcherkassova, Anna I. Prostyakova, Sergei A. Tsurkan, Nikolai V. Suganov, Alexander M. Boroda, Angelina V. Zhilenkova, Juliya N. Pirogova, Zaiana D. Sangadzhieva, Aleksandr S. Rusanov, Aleksandr A. Rozhkov, Anastasia S. Fatyanova, Natalia M. Nikitina, Nikolay N. Bagmet, Marina I. Sekacheva

“…CA-62 glycoprotein showed the highest level of expression at stage I NSCLC (12 745 U/mL) compared to other tumor markers studied and remained very high at the later stages of cancer: stage II (11 261 U/mL) and stage III (10 220 U/mL). …”
Get full text

Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study by Jianxing He, ProfMD, Bo Wang, BS, Jinsheng Tao, MSc, Qin Liu, MM, Minhua Peng, PhD, Shan Xiong, MD, Jianfu Li, MD, Bo Cheng, MD, Caichen Li, MD, Shunjun Jiang, MD, Xiangcheng Qiu, BS, Yang Yang, MB, Zhujia Ye, PhD, Fanrui Zeng, MD, Jian Zhang, ProfMD, Dan Liu, ProfMD, Weimin Li, ProfMD, Zhiwei Chen, PhD, Qingsi Zeng, ProfMD, Jian-Bing Fan, ProfPhD, Wenhua Liang, ProfMD

“…A high sensitivity of 0·98 (0·96–0·99) was maintained in early-stage lung cancer (stages 0 and I) and 0·99 (0·96–1·00) in 5–10 mm nodules. …”
Get full text